• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

    12/13/23 7:55:44 AM ET
    $AAMC
    $ATNF
    $BURU
    $CCCC
    Real Estate
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AAMC alert in real time by email

    Shares of ReShape Lifesciences Inc. (NASDAQ:RSLS) rose sharply in pre-market trading after the company said it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX.

    ReShape Lifesciences shares jumped 44.6% to $0.3630 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • RiskOn International, Inc. (NASDAQ:ROI) shares rose 84.3% to $0.2678 in pre-market trading after declining 9% on Tuesday.
    • Innovative International Acquisition Corp. (NASDAQ:IOAC) shares rose 28.6% to $10.93 in pre-market trading.
    • C4 Therapeutics, Inc. (NASDAQ:CCCC) gained 28.6% to $3.01 in pre-market trading after the company announced positive data from CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma. Stifel upgraded C4 Therapeutics from Hold to Buy and raised the price target from $2 to $12.
    • Mynaric AG (NASDAQ:MYNA) shares surged 16.9% to $5.60 in pre-market trading after the company received a $33 million order from Northrop Grumman.
    • MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) shares gained 16.5% to $0.31 in pre-market trading. MyMD Pharmaceuticals recently Received a notice of allowance for its U.S. patent application 17/851,862 titled "Method of Treating Diseases of the Visual System."
    • 180 Life Sciences Corp. (NASDAQ:ATNF) gained 15.6% to $0.2169 in pre-market trading after falling 6% on Tuesday.
    • CISO Global Inc. (NASDAQ:CISO) shares rose 14.9% to $0.11 in pre-market trading after falling 7% on Tuesday.
    • Aurora Mobile Limited (NASDAQ:JG) shares gained 14.1% to $2.83 in pre-market trading. Aurora Mobile said its subsidiary Wuhan SendCloud Technology Co., Ltd. has entered into a strategic partnership with Beijing Muhua Information Technology Co., Ltd.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares climbed 14% to $1.06 in pre-market trading after surging 29% on Tuesday.

    Losers

    • Jin Medical International Ltd. (NASDAQ:ZJYL) shares fell 13.1% to $27.10 in pre-market trading.
    • Altisource Asset Management Corporation (NYSE:AAMC) shares fell 12.4% to $5.25 in pre-market trading after declining around 8% on Tuesday.
    • Edesa Biotech, Inc. (NASDAQ:EDSA) fell 11.8% to $4.57 in pre-market trading after jumping 11% on Tuesday.
    • Mobilicom Limited (NASDAQ:MOB) shares fell 10.9% to $1.55 in pre-market trading after gaining over 5% on Tuesday.
    • Shengfeng Development Limited (NASDAQ:SFWL) shares fell 10.4% to $13.00 in pre-market trading.
    • Nuburu, Inc. (NASDAQ:BURU) shares fell 10.3% to $0.14 in pre-market trading.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) fell 10.2% to $0.4730 in pre-market after gaining 7% on Tuesday.
    • IN8bio, Inc. (NASDAQ:INAB) shares fell 8.8% to $1.49 in pre-market trading after jumping 28% on Tuesday. IN8bio recently announced updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.
    • Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) fell 8.3% to $1.14 in pre-market trading. Petros Pharmaceuticals recently completed a Human Factors Study to assess the technology component developed to facilitate patient's access to STENDRA.
    • VS MEDIA Holdings Limited (NASDAQ:VSME) fell 7.7% to $0.5720 in pre-market trading after declining 5% on Tuesday.

     

    Now Read This: ABM Industries, Adobe And 3 Stocks To Watch Heading Into Wednesday

    Get the next $AAMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAMC
    $ATNF
    $BURU
    $CCCC

    CompanyDatePrice TargetRatingAnalyst
    C4 Therapeutics Inc.
    $CCCC
    12/2/2025Buy
    TD Cowen
    C4 Therapeutics Inc.
    $CCCC
    9/17/2025$8.00Overweight
    Barclays
    C4 Therapeutics Inc.
    $CCCC
    9/15/2025$6.00Equal-Weight → Overweight
    Stephens
    C4 Therapeutics Inc.
    $CCCC
    9/4/2025$8.00Buy
    Guggenheim
    C4 Therapeutics Inc.
    $CCCC
    12/19/2024$8.00 → $12.00Equal Weight → Overweight
    Wells Fargo
    C4 Therapeutics Inc.
    $CCCC
    11/18/2024$4.00Equal-Weight
    Stephens
    IN8bio Inc.
    $INAB
    3/18/2024$7.50Buy
    Laidlaw
    Aurora Mobile Limited
    $JG
    3/12/2024$7.00Neutral → Buy
    Alliance Global Partners
    More analyst ratings

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wang Jin Johnny

    3 - SHENGFENG DEVELOPMENT Ltd (0001863218) (Issuer)

    4/13/26 6:42:38 AM ET
    $SFWL
    Trucking Freight/Courier Services
    Industrials

    SEC Form 4 filed by Nijhawan Pardeep

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    4/10/26 5:02:20 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Anderson Kenneth Carl

    4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

    4/3/26 10:45:54 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $39,000 worth of shares (10,000 units at $3.90) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/6/26 5:01:15 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $42,560 worth of shares (10,000 units at $4.26) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/5/26 5:01:11 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NUBURU Accelerates Maddox Defense JV with Funded Prototype Build Phase, Targeting Near-Term U.S. Government Demonstration and Entry Into $20B+ Counter-Drone Market

    Execution advances into prototype production phase, supporting drone and mission-critical pod manufacturing, with secured initial capital and milestone-based funding structure NUBURU, Inc. (NYSE:BURU), a dual-use Defense & Security platform company focused on non-kinetic effects, directed-energy technologies, electronic warfare and software-orchestrated defense systems, today announced a further acceleration of its joint venture with Maddox Defense Incorporated ("Maddox Defense"), with the program now advancing into the production phase of its first Mobile Additive Manufacturing Container (MAMC) platform, designed for the production of drones, mission-critical pods, and related defense co

    4/9/26 7:45:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Aurora Mobile Debuts Modellix: A Unified Gateway for Next-Gen AI Media Generation

    SINGAPORE, April 09, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services, today announced the official launch of Modellix.ai, a unified multimodal AI platform that provides a seamless, standardized bridge to global elite image and video models, transforming fragmented AI capabilities into scalable business innovation. (Image from Modellix.ai) Solving the Fragmentation Crisis in Generative AIAs generative AI adoption continues to accelerate, businesses and developers increasingly rely on multiple model providers to support image generation, video generation, image editing

    4/9/26 7:00:00 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

    Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche ((SIX: RO, ROP, OTCQX:RHHBY) to ad

    4/9/26 6:59:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAMC
    $ATNF
    $BURU
    $CCCC
    SEC Filings

    View All

    C4 Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    4/10/26 7:17:23 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    4/9/26 7:07:35 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CISO Global Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - CISO Global, Inc. (0001777319) (Filer)

    4/8/26 8:30:36 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on C4 Therapeutics

    TD Cowen initiated coverage of C4 Therapeutics with a rating of Buy

    12/2/25 8:23:26 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on C4 Therapeutics with a new price target

    Barclays initiated coverage of C4 Therapeutics with a rating of Overweight and set a new price target of $8.00

    9/17/25 8:06:28 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics upgraded by Stephens with a new price target

    Stephens upgraded C4 Therapeutics from Equal-Weight to Overweight and set a new price target of $6.00

    9/15/25 8:00:09 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Leadership Updates

    Live Leadership Updates

    View All

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    CISO Global Lands 30 Year Sales Veteran Michael Czerneda to Ignite the Next Wave of Software Growth

    New Vice President of Sales to accelerate software-driven growth across cyber services platform and insurance distribution channels  Scottsdale, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Michael Czerneda as Vice President of Sales. In this role, Czerneda will lead enterprise-wide sales initiatives as the Company accelerates its transition toward scalable, software-driven growth built on its established cyber services platform.  Czerneda brings more than 30 years of sales leadership experience spanning UCaaS, CCaaS, da

    2/18/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    CISO Global Partners with TeleDental to Launch CyberSimple® Powered by CHECKLIGHT® to Protect Dental Clinics From Cyber Threats

    Scottsdale, AZ, Jan. 15, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO), a leading provider of AI-powered cybersecurity software and compliance services, today announced a strategic partnership with TeleDental.com and DentalChat.com to offer Cyber Assurance Group's CyberSimple® powered by CHECKLIGHT®, delivering cybersecurity and financial protection purpose-built for dental practices. Through this collaboration, CyberSimple® powered by CHECKLIGHT® will be made available via TeleDental.com and DentalChat.com, initially extending protection to more than 358 dental clinics nationwide, with significant expansion potential across the broader U.S. dental market. This effort underline

    1/15/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Financials

    Live finance-specific insights

    View All

    Mobilicom Reports 2025 Year-End Financial Results

    A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years  Cash and cash equivalents surge 120% to $19.1 million following $12.6 million in 2025 warrants exercise and equity raises With revenues up year-over-year at $3.4 million, monthly operating cash burn was cut by 41% to ~$159K — lowest in Company history — with zero-debt on balance sheet Launch of industry-first Secured Autonomy™ cybersecurity framework, multiple new design wins across Europe, Middle East and South Asia, and expanded U.S. Tier-1 drone production-scale orders drive multi-market momentum Webcast scheduled for 4:30 pm E

    3/23/26 4:06:00 PM ET
    $MOB
    Aerospace
    Industrials

    Mobilicom to Report Full Year 2025 Financial and Operating Results on March 23, 2026

    Palo Alto, California, March 16, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced that it will issue a press release with its financial and operational results for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Monday, March 23, 2026. The Company will also discuss its results and other corporate developments, followed by a Q&A session, on a conference call at 4:30 p.m. EST the same day. Investors are invited to email questions to the Company in advance to: [email protected]. Conference call & webcast info: Monda

    3/16/26 8:00:00 AM ET
    $MOB
    Aerospace
    Industrials

    Aurora Mobile Limited Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    SHENZHEN, China, March 12, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited ("Aurora Mobile" or the "Company") (NASDAQ:JG), a leading provider of customer engagement and marketing technology services, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Mr. Weidong Luo, Chairman and Chief Executive Officer of Aurora Mobile, commented, "2025 marks the first time in our history that we recorded full-year net profit on a GAAP basis! In addition, we delivered an incredible fourth quarter of 2025 where: Total revenue surpassed the RMB100 million mark to reach RMB105.2 million, representing a remarkable 13% year-over-year and 16% sequen

    3/12/26 6:30:00 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    $AAMC
    $ATNF
    $BURU
    $CCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nuburu Inc.

    SC 13D/A - Nuburu, Inc. (0001814215) (Subject)

    11/25/24 8:59:19 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13G/A filed by C4 Therapeutics Inc.

    SC 13G/A - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 7:53:04 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by C4 Therapeutics Inc.

    SC 13G - C4 Therapeutics, Inc. (0001662579) (Subject)

    11/14/24 6:43:36 PM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care